Titanium dioxide
Anthelios (titanium dioxide) is a small molecule pharmaceutical. Titanium dioxide was first approved as Anthelios 20 on 2006-10-05.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Anthelios
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| OTC monograph final | 2013-01-07 | |
| 100 % mineral spf mini set | OTC monograph final | 2021-12-09 |
| 100% mineral body mist with green tea extract broad spectrum spf 50 | OTC monograph final | 2022-10-11 |
| 100% mineral broad spectrum sunscreen spf 30 | C200263 | 2024-12-18 |
| 100% mineral broad spectrum sunscreen spf 50 | C200263 | 2024-12-05 |
| 100% pure everywhere sunscreen | OTC monograph not final | 2017-05-01 |
| 15hr cover lasting | OTC monograph not final | 2015-09-21 |
| 1926 since derm acte 365 uv screen | OTC monograph final | 2023-07-20 |
| 1926 since derm acte uv screen spf 30 | OTC monograph final | 2023-07-16 |
| 3lab perfect lite sunscreen spf 30 broad spectrum | C200263 | 2023-12-12 |
Show 1677 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| photosensitivity disorders | — | D010787 | L57.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
138 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 1 | — | 3 | 4 | 8 |
| Infections | D007239 | EFO_0000544 | — | — | — | 2 | 1 | 3 | 6 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 1 | — | 2 | 2 | 5 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | 1 | 3 | 5 |
| Dentin sensitivity | D003807 | — | — | 1 | — | — | 1 | 3 | 5 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 1 | 1 | 1 | 4 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 3 | 1 | 4 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | — | — | 1 | 1 | 3 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 2 | — | 1 | — | 3 |
| Sclerosis | D012598 | — | — | 1 | 2 | — | 1 | — | 3 |
Show 23 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | 1 | — | 4 | 5 |
| Covid-19 | D000086382 | — | U07.1 | — | — | 2 | — | — | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 2 | — | — | 2 |
| Postoperative complications | D011183 | — | — | — | — | 2 | — | — | 2 |
| Gestational diabetes | D016640 | — | O24.4 | — | — | 1 | — | — | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | — | 1 | — | — | 1 |
| Pulpitis | D011671 | EFO_1001139 | K04.0 | — | — | 1 | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | — | — | 1 | — | — | 1 |
| Medulloblastoma | D008527 | — | — | — | — | 1 | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | — | 1 | 4 |
| Pinealoma | D010871 | — | — | — | 1 | — | — | 1 | 2 |
| Hepatitis c | D006526 | — | B19.2 | — | 1 | — | — | 1 | 2 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | 1 | 1 | — | — | 1 | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 2 | — | — | — | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | 1 | 1 | — | — | 1 | 2 |
| Candidiasis | D002177 | — | B37 | — | 1 | — | — | 1 | 2 |
| Bronchiectasis | D001987 | — | J47 | — | 1 | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomatitis | D013280 | EFO_1001904 | K12.1 | 1 | — | — | — | 3 | 4 |
| Denture stomatitis | D013282 | EFO_1000893 | K12.1 | 1 | — | — | — | 3 | 4 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | — | — | — | 1 | 2 |
| Colitis | D003092 | EFO_0003872 | K52.9 | 1 | — | — | — | 1 | 2 |
| Ulcer | D014456 | MPATH_579 | — | 1 | — | — | — | 1 | 2 |
| Hiv | D006678 | — | O98.7 | 1 | — | — | — | — | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | — | — | — | — | 1 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peri-implantitis | D057873 | EFO_1001390 | — | — | — | — | — | 2 | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 2 | 2 |
| Microbiota | D064307 | — | — | — | — | — | — | 2 | 2 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 2 | 2 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
| Body composition | D001823 | — | — | — | — | — | — | 2 | 2 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 2 | 2 |
| Carotid stenosis | D016893 | — | — | — | — | — | — | 1 | 1 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 1 | 1 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | — | 1 | 1 |
Show 75 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Titanium dioxide |
| INN | — |
| Description | Titanium dioxide is a titanium oxide with the formula TiO2. A naturally occurring oxide sourced from ilmenite, rutile and anatase, it has a wide range of applications. It has a role as a food colouring. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 13463-67-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201136 |
| ChEBI ID | 32234 |
| PubChem CID | 26042 |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 96,117 documents
View more details
Safety
Black-box Warning
Black-box warning for: Josie maran argan daily moisturizer spf47, Josie maran argan daily moisturizer spf47 protect and perfect, Josie maran argan daily moisturizer spf47 protect and perfect radiance, Luminizing moisture tint sunscreen broad spectrum spf 20, Matte moisture tint sunscreen broad spectrum spf 15, Minus-sol facial sun protection spf 30 plus ivory, Minus-sol facial sun protection spf 30 plus white, Skin tint fx
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
894 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use